Latest Period
Q1 2026
Security Snapshot
Cytek Biosciences, Inc. - Common Stock, par value $0.001 per share (CTKB) Institutional Ownership
CUSIP: 23285D109
13F Institutional Holders and Ownership History from Q3 2021 to Q1 2026
Institutions Reporting
163
Shares (Excl. Options)
85,067,527
Price
$4.37
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Symbol
- CTKB on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 85,067,527
- Total 13F value
- $371,768,728
- Portfolio coverage rank
- 0%
- Share change
- +2,714,567
- Value change
- +$11,134,305
- Number of holders
- 163
- Shares outstanding
- 129,063,934
- SEC-reported price per share
- $3.68
- Insider filing price
- $3.68
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- CTKB - Cytek Biosciences, Inc. - Common Stock, par value $0.001 per share is tracked under CUSIP 23285D109.
- 163 institutions reported positions in Q1 2026.
- 4 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 155 to 163 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $414,284,117 to $371,768,728.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 163 institutions filings for Q1 2026.
Security key
23285D109
Latest holder period
Q1 2026
13F holders
163
13D/G owners
4
CIK / CUSIP context first
Open Q1 2026 holders
CTKB full holder history
Cytek Biosciences, Inc. SEC filings
Cytek Biosciences, Inc. company facts
Cytek Biosciences, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 23285D109:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
4
Security
CTKB
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BlackRock, Inc. | 13% | -8.6% | $56,208,317 | -$6,633,186 | 16,531,858 | -11% | BlackRock, Inc. | 30 Jun 2025 |
| MILLENNIUM MANAGEMENT LLC | 6.1% | +18% | $34,404,573 | +$5,392,899 | 7,872,900 | +19% | Millennium Management LLC | 11 May 2026 |
| Topline Capital Management, LLC | 5.3% | $28,140,515 | 6,780,847 | Topline Capital Management, LLC | 25 Sep 2025 | |||
| BROWN CAPITAL MANAGEMENT LLC | 3.9% | -33% | $17,204,316 | -$8,695,650 | 4,958,016 | -34% | Brown Capital Management, LLC | 30 Sep 2025 |
As of 31 Mar 2026, 163 institutional investors reported holding 85,067,527 shares of Cytek Biosciences, Inc. - Common Stock, par value $0.001 per share (CTKB). This represents 66% of the company’s total 129,063,934 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
59%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | 13% | 17,007,269 | -0.97% | 0% | $74,321,765 |
| Topline Capital Management, LLC | 5.5% | 7,064,481 | -5.1% | 5.1% | $30,871,782 |
| HHLR ADVISORS, LTD. | 5.2% | 6,657,030 | 0% | 1.7% | $29,091,221 |
| MILLENNIUM MANAGEMENT LLC | 4.9% | 6,291,798 | +32% | 0.02% | $27,495,157 |
| Boston Partners | 4.5% | 5,802,773 | +16% | 0.03% | $25,361,674 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.7% | 4,762,904 | 0% | 0% | $20,813,890 |
| STATE STREET CORP | 3.2% | 4,123,748 | -0.56% | 0% | $18,020,779 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.2% | 2,833,955 | +1.6% | 0% | $12,387,379 |
| DIMENSIONAL FUND ADVISORS LP | 2.1% | 2,663,329 | +0.62% | 0% | $11,638,019 |
| GOLDMAN SACHS GROUP INC | 1.8% | 2,344,735 | +31% | 0% | $10,246,491 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 1.8% | 2,311,858 | 0% | 0% | $10,102,819 |
| MORGAN STANLEY | 1.3% | 1,718,875 | +1.1% | 0% | $7,511,483 |
| ROYCE & ASSOCIATES LP | 1.3% | 1,642,368 | -3% | 0.07% | $7,177,148 |
| BROWN CAPITAL MANAGEMENT LLC | 1.1% | 1,480,506 | -29% | 0.92% | $6,469,811 |
| Russell Investments Group, Ltd. | 1.1% | 1,359,900 | +36% | 0.01% | $5,942,759 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.86% | 1,104,601 | +0.92% | 0% | $4,827,106 |
| BANK OF AMERICA CORP /DE/ | 0.78% | 1,009,054 | +18% | 0% | $4,409,567 |
| NORTHERN TRUST CORP | 0.78% | 1,005,193 | +5% | 0% | $4,392,693 |
| AQR CAPITAL MANAGEMENT LLC | 0.71% | 912,342 | +23% | 0% | $3,986,935 |
| Simcoe Capital LLC | 0.68% | 882,113 | +196% | 3.5% | $3,854,834 |
| CenterBook Partners LP | 0.57% | 729,874 | 0.17% | $3,189,549 | |
| VANGUARD FIDUCIARY TRUST CO | 0.56% | 717,011 | 0% | 0% | $3,133,338 |
| RENAISSANCE TECHNOLOGIES LLC | 0.52% | 676,700 | +0.25% | 0% | $2,957,179 |
| Bank of New York Mellon Corp | 0.47% | 608,647 | -4.6% | 0% | $2,659,788 |
| PRINCIPAL FINANCIAL GROUP INC | 0.41% | 534,759 | -20% | 0% | $2,336,897 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
19
Latest
Q1 2026
Rows shown
1-19 of 19
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 85,067,527 | $371,768,728 | +$11,134,305 | $4.37 | 163 |
| 2025 Q4 | 82,036,336 | $414,284,117 | +$11,052,705 | $5.05 | 155 |
| 2025 Q3 | 79,927,508 | $277,365,376 | +$1,944,386 | $3.47 | 150 |
| 2025 Q2 | 79,443,660 | $270,126,999 | +$5,595,600 | $3.40 | 156 |
| 2025 Q1 | 77,562,435 | $311,007,504 | -$4,129,971 | $4.01 | 159 |
| 2024 Q4 | 77,254,066 | $501,381,338 | +$11,940,410 | $6.49 | 150 |
| 2024 Q3 | 74,960,438 | $415,264,156 | -$14,542,700 | $5.54 | 134 |
| 2024 Q2 | 76,158,342 | $424,969,676 | -$33,289,478 | $5.58 | 126 |
| 2024 Q1 | 80,524,601 | $540,295,292 | +$11,110,651 | $6.71 | 119 |
| 2023 Q4 | 78,933,920 | $719,883,797 | +$17,961,713 | $9.12 | 101 |
| 2023 Q3 | 77,486,686 | $427,726,918 | -$3,527,385 | $5.52 | 106 |
| 2023 Q2 | 77,036,054 | $657,934,234 | +$69,958,551 | $8.54 | 100 |
| 2023 Q1 | 68,508,151 | $629,603,408 | +$39,123,355 | $9.19 | 100 |
| 2022 Q4 | 64,201,674 | $655,512,030 | +$29,671,547 | $10.21 | 100 |
| 2022 Q3 | 61,170,760 | $900,430,367 | +$128,781,199 | $14.72 | 87 |
| 2022 Q2 | 52,912,941 | $567,776,021 | +$56,303,644 | $10.73 | 81 |
| 2022 Q1 | 47,712,980 | $514,520,453 | +$122,459,757 | $10.78 | 72 |
| 2021 Q4 | 35,038,930 | $571,924,873 | -$4,872,187 | $16.32 | 51 |
| 2021 Q3 | 34,351,929 | $744,420,532 | +$744,420,530 | $21.41 | 53 |